Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Ahmad Usmani

Anesthesiology Bedford, NH Medical Doctor

NPI 1407834831 CMS profile 245870

160 S River Rd, Bedford, NH 03110

Open in the dashboard

General payments

$269

13 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ahmad Usmani of Bedford, NH is reported in the CMS Open Payments database as having received $269 across 13 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $30 1
2024 General $46 2
2023 General $69 3
2022 General $72 4
2021 General $39 2
2020 General $12 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ahmad Usmani
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to Ahmad Usmani were reported at $30. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year Ahmad Usmani Anesthesiology median Middle half National median
2019 $0 $72 $23–$151 $163
2020 $12 $36 $17–$120 $114
2021 $39 $49 $21–$135 $132
2022 $72 $52 $22–$144 $149
2023 $69 $53 $23–$143 $160
2024 $46 $55 $25–$150 $164
2025 $30 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Boston Scientific Corporation $87 4 payments
  2. Medtronic, Inc. $57 3 payments
  3. Abbott Laboratories $43 2 payments
  4. Averitas Pharma Inc. $30 1 payment
  5. Stryker Corporation $23 1 payment
  6. Relievant Medsystems, Inc. $17 1 payment
  7. Medtronic USA, Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $269 13 payments
Products named General payments · program years 2020–2025
  1. WaveWriter Alpha Prime 16 $46 2 payments
  2. PROCLAIM $43 2 payments
  3. Qutenza $30 1 payment
  4. IVAS $23 1 payment
  5. RESTORE $21 1 payment
  6. General - Pain Management $19 1 payment
  7. INTELLIS $18 1 payment
  8. INTELLIS ADAPTIVESTIM $18 1 payment
  9. Intracept Pain $17 1 payment
  10. Intracept Pain $17 1 payment
  11. Other $12 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

206

Median for Pain Management: 951

Drug cost

$3,009

Median for Pain Management: $26,034

Branded share of claims

0%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 84 $1,402
Oxycodone Hcl Generic 71 $1,020
Tramadol Hcl Generic 28 $274
Tizanidine Hcl Generic 12 $168
Methadone Hcl Generic 11 $145

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$173,408

Of which drugs: $4,202

Medicare patients

214

Average age 75

Services billed

3,506

148 women, 66 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 71%
Depression 36%
Osteoporosis 29%
Chronic kidney disease 26%
COPD 24%
Heart failure 22%
Ischemic heart disease 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 52 640 $3,542
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 79 774 $579
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 106 154 $16

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

13 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anesthesiology in New Hampshire

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record